reports
- Jean-François Granjon
- Jean-François Granjon
- Jerôme Bodin
- Thomas Zlowodzki
- Jerôme Bodin
- Thomas Zlowodzki
- Martial Descoutures
- Oussema Denguir
- Jamila El Bougrini
- Thibaut Voglimacci-Stephanopoli
- Martijn Den Drijver
AMG : Some downside and some potential upside, yet no immediate cataly...
We up our estimates on the back of the stronger performance of antimony in AMG Technologies and the outlook for AMG Vanadium (recovery in yield and output, addition of US chrome business). Even though we continue to assume flat lithium prices, which means modest profitability for AMG Lithium, the overall results is that we raise our 2026-2027 sales estimate by 8% and 20% and our adj. EBITDA estimates by 2% and 15%. But as the share price has already rallied close to 50% in the last three months,...
- Jerôme Bodin
- Jerôme Bodin
- Klaus Ringel
- Michael Foundoukidis
- Nicolas Thorez
- Martial Descoutures
- Oussema Denguir
- Nicolas Thorez
Availability of Transgene’s Half-Year Financial Report as of June 30, ...
Availability of Transgene’s Half-Year Financial Report as of June 30, 2025 TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2025. The document is available on the Company’s website: , in the “Investors/Financial information” section. This report comprises the following documents: 2025 half-year financial statements;Half-year management report;Statutory Auditors’ report on the 2025 half-year financial statements;Declaration by the person responsible for this hal...
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG405...
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data Randomization to be Completed in Phase II Part in Q4 2025 2025 Half-Year Results and Business Update Positive Phase I data with TG4050 in operable Head and Neck Squamous Cell Carcinoma (HNSCC) 100% disease-free survival after 2 years of follow-up — data presented in a rapid oral presentation at ASCO (June 2025) Transgene to report additional immunological data at a scientific conference in Q4 2025 Ongoing Phase II part with TG4050 in operable HNSCC Patient screening comp...
Données positives de la Phase I randomisée de TG4050, vaccin thérapeut...
Données positives de la Phase I randomisée de TG4050, vaccin thérapeutique individualisé néoantigénique contre le cancer – Fin de la randomisation de la partie Phase II au quatrième trimestre 2025 Résultats financiers du 1er semestre 2025 et point sur l’activité Données positives de Phase I évaluant TG4050 dans les cancers opérables de la tête et du cou1 100 % de survie sans récidive après deux ans de suivi des patients – Données communiquées lors d’une présentation orale à l’ASCO (juin 2025)Présentation de nouvelles données d’immunologie lors d’une conférence scientifique au quatrième t...
Mise à disposition du Rapport Financier Semestriel au 30 juin 2025
Mise à disposition du Rapport Financier Semestriel au 30 juin 2025 TRANSGENE (Paris : TNG) annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers le rapport semestriel au 30 juin 2025. Il peut être consulté sur le site internet de la société à l’adresse suivante : , dans la rubrique « Investisseurs – Informations financières ». Le rapport semestriel comprend les documents suivants : Information financière semestrielle 2025 ;Rapport semestriel d’activité ;Rapport des commissaires aux comptes sur l’information financière semestrielle 2025 ;Attes...
ASSYSTEM: First-half 2025 results
ASSYSTEM: First-half 2025 results First-half 2025 results Revenue: solid performance (up 4.7% on an organic basis)Operating profit before non-recurring items (EBITA)(1): €20.4 million (up 10.2%)EBITA margin: 6.2% (up 0.1 pt) Paris La Défense, 16 September 2025, 5.35 p.m. (CEST) – At its meeting held today, the Board of Directors of Assystem S.A. (ISIN: FR0000074148 - ASY), an international engineering group, reviewed the Group’s financial statements for the six months ended 30 June 2025. Dominique Louis, Assystem's Chairman & CEO, stated: “The Group's growth was driven by the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.